Literature DB >> 9395464

Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor.

C J Mann1, A A Troussard, F T Yen, N Hannouche, J Najib, J C Fruchart, V Lotteau, P André, B E Bihain.   

Abstract

ApoC-III overexpression in mice results in severe hypertriglyceridemia due primarily to a delay in the clearance of triglyceride-rich lipoproteins. We have, in primary cultures of rat hepatocytes, characterized a lipolysis-stimulated receptor (LSR). The apparent number of LSR that are available on rat liver plasma membranes is negatively correlated with plasma triglyceride concentrations measured in the fed state. We therefore proposed that the primary physiological role of the LSR is to contribute to the cellular uptake of triglyceride-rich lipoproteins. We have now tested the effect of apoC-III on the binding of triglyceride-rich lipoproteins to LSR. Supplementation of 125I-very low density lipoprotein (VLDL) with apoC-III inhibited the LSR-mediated binding, internalization, and degradation of 125I-VLDL in primary cultures of rat hepatocytes. Studies using isolated rat liver plasma membranes showed that enrichment of human VLDL and chylomicrons with synthetic or purified human apoC-III decreased their binding to the LSR by about 40%. Supplementation of triglyceride-rich lipoproteins under the same conditions with human apoC-II had no such inhibitory effect, despite the fact that this apoprotein bound as efficiently as apoC-III to these particles. Preincubation of LDL with apoC-III did not modify its binding to LSR. Partitioning studies using 125I-apoC-III showed that this lack of effect was due to apoC-III's inability to efficiently associate with LDL. Purified human apoC-III1 was as efficient as the synthetic nonsialylated form of apoC-III in inhibiting binding of VLDL to LSR. However, despite a 2-fold greater binding of apoC-III2 to VLDL, this isoform was a less efficient inhibitor of the binding of VLDL to LSR than apoC-III1 or nonsialylated apoC-III. Desialylation of apoC-III2 by treatment with neuraminidase increased the inhibition of VLDL binding to LSR to a level similar to that observed with apoC-III1 and nonsialylated apoC-III. We propose that apoC-III regulates in part the rate of removal of triglyceride-rich particles by inhibiting their binding to the LSR, and that the level of inhibition is determined by the degree of apoC-III sialylation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9395464     DOI: 10.1074/jbc.272.50.31348

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Comparison of diets high in monounsaturated versus polyunsaturated fatty acid on postprandial lipoproteins in diabetes.

Authors:  C Madigan; M Ryan; D Owens; P Collins; G H Tomkin
Journal:  Ir J Med Sci       Date:  2005 Jan-Mar       Impact factor: 1.568

2.  RNA-seq analysis provide new insights into mapk signaling of apolipoproteinciii-induced inflammation in porcine vascular endothelial cells.

Authors:  Yuan Yue; Hao Jiang; Shouqing Yan; Yao Fu; Chang Liu; Xulei Sun; Menglong Chai; Yan Gao; Bao Yuan; Chengzhen Chen; Lisheng Dai; Jiabao Zhang; Yu Ding
Journal:  Cell Cycle       Date:  2017-09-21       Impact factor: 4.534

3.  Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

Authors:  Esther M M Ooi; Doris T Chan; Gerald F Watts; Dick C Chan; Theodore W K Ng; Gursharan K Dogra; Ashley B Irish; P Hugh R Barrett
Journal:  J Lipid Res       Date:  2011-02-06       Impact factor: 5.922

4.  APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.

Authors:  Xiaoyun Cheng; Jun Yamauchi; Sojin Lee; Ting Zhang; Zhenwei Gong; Radhika Muzumdar; Shen Qu; H Henry Dong
Journal:  J Biol Chem       Date:  2017-01-23       Impact factor: 5.157

5.  Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions.

Authors:  Saulo Mendoza; Olgica Trenchevska; Sarah M King; Randall W Nelson; Dobrin Nedelkov; Ronald M Krauss; Hussein N Yassine
Journal:  J Clin Lipidol       Date:  2016-12-28       Impact factor: 4.766

6.  Effect of dietary cholesterol oxidation products on the plasma clearance of chylomicrons in the rat.

Authors:  D F Vine; K D Croft; L J Beilin; J C L Mamo
Journal:  Lipids       Date:  2002-05       Impact factor: 1.880

7.  Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes.

Authors:  Juraj Koska; Hussein Yassine; Olgica Trenchevska; Shripad Sinari; Dawn C Schwenke; Frances T Yen; Dean Billheimer; Randall W Nelson; Dobrin Nedelkov; Peter D Reaven
Journal:  J Lipid Res       Date:  2016-03-03       Impact factor: 5.922

8.  Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice.

Authors:  Yun-Zi Liu; Xiaoyun Cheng; Ting Zhang; Sojin Lee; Jun Yamauchi; Xiangwei Xiao; George Gittes; Shen Qu; Chun-Lei Jiang; H Henry Dong
Journal:  J Biol Chem       Date:  2016-05-11       Impact factor: 5.157

9.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

10.  Liver-specific loss of lipolysis-stimulated lipoprotein receptor triggers systemic hyperlipidemia in mice.

Authors:  Prachiti Narvekar; Mauricio Berriel Diaz; Anja Krones-Herzig; Ulrike Hardeland; Daniela Strzoda; Sigrid Stöhr; Marcus Frohme; Stephan Herzig
Journal:  Diabetes       Date:  2009-02-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.